These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

283 related items for PubMed ID: 20201608

  • 1. Efficacy and safety of the combined oral contraceptive ethinylestradiol/drospirenone (Yasmin) in healthy Chinese women: a randomized, open-label, controlled, multicentre trial.
    Guang-Sheng F, Mei-Lu B, Li-Nan C, Xiao-Ming C, Zi-Rong H, Zi-Yan H, Xiao-Ping J, Jian L, Shu-Ying W, Cheng-Liang X, Zheng-Ai X, Tian-Fu Y.
    Clin Drug Investig; 2010; 30(6):387-96. PubMed ID: 20201608
    [Abstract] [Full Text] [Related]

  • 2. Ethinylestradiol/drospirenone: a review of its use as an oral contraceptive.
    Keam SJ, Wagstaff AJ.
    Treat Endocrinol; 2003; 2(1):49-70. PubMed ID: 15871554
    [Abstract] [Full Text] [Related]

  • 3. Effects of oral contraceptives containing ethinylestradiol with either drospirenone or levonorgestrel on various parameters associated with well-being in healthy women: a randomized, single-blind, parallel-group, multicentre study.
    Kelly S, Davies E, Fearns S, McKinnon C, Carter R, Gerlinger C, Smithers A.
    Clin Drug Investig; 2010; 30(5):325-36. PubMed ID: 20384388
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Cycle control and bleeding pattern of a 24/4 regimen of drospirenone 3 mg/ethinylestradiol 20 μg compared with a 21/7 regimen of desogestrel 150 μg/ethinylestradiol 20 μg: a pooled analysis.
    Anttila L, Neunteufel W, Petraglia F, Marr J, Kunz M.
    Clin Drug Investig; 2011; 31(8):519-525. PubMed ID: 21721590
    [Abstract] [Full Text] [Related]

  • 8. An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen.
    Parsey KS, Pong A.
    Contraception; 2000 Feb; 61(2):105-11. PubMed ID: 10802275
    [Abstract] [Full Text] [Related]

  • 9. Multicenter trial of two monophasic oral contraceptives containing 30 mcg ethinylestradiol and either desogestrel or gestodene in Thai women.
    Koetsawang S, Charoenvisal C, Banharnsupawat L, Singhakovin S, Kaewsuk O, Punnahitanont S.
    Contraception; 1995 Apr; 51(4):225-9. PubMed ID: 7796587
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Efficacy and safety of drospirenone-ethinylestradiol on contraception in healthy Chinese women: a multicenter randomized controlled trial].
    Fan GS, Bian ML, Cheng LN, Cao XM, Huang ZR, Han ZY, Jing XP, Li J, Wu SY, Xiong CL, Xiong ZA, Yue TF.
    Zhonghua Fu Chan Ke Za Zhi; 2009 Jan; 44(1):38-44. PubMed ID: 19563061
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Cycle control, safety and efficacy of a 24-day regimen of gestodene 60 microg/ ethinylestradiol 15 microg and a 21-day regimen of desogestrel 150 microg/ethinylestradiol 20 microg.
    Eur J Contracept Reprod Health Care; 1999 Nov; 4 Suppl 2():17-25. PubMed ID: 14677621
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Comparison of change in body weight between contraception containing 30-μg ethinylestradiol/2-mg chlormadinone acetate or 30-μg ethinylestradiol/3-mg drospirenone: a randomised controlled trial.
    Wongwananuruk T, Panichyawat N, Panchalee T, Jirakittidul P, Angsuwathana S, Sirimai K, Thamkhantho M, Chiravacharadej G.
    Eur J Contracept Reprod Health Care; 2020 Feb; 25(1):43-48. PubMed ID: 31756117
    [Abstract] [Full Text] [Related]

  • 18. Experiences with Yasmin: the acceptability of a novel oral contraceptive and its effect on well-being.
    Mansour D.
    Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():35-41; discussion 42-3. PubMed ID: 12659405
    [Abstract] [Full Text] [Related]

  • 19. The acceptability of a novel oral contraceptive containing drospirenone and its effect on well-being.
    Boschitsch E, Skarabis H, Wuttke W, Heithecker R.
    Eur J Contracept Reprod Health Care; 2000 Dec; 5 Suppl 3():34-40. PubMed ID: 11246600
    [Abstract] [Full Text] [Related]

  • 20. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
    Cianci A, De Leo V.
    Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.